Evidence map›Paper›PMID 36400835›Full record

ArticleCommunications biology2022

Molecular recognition of a membrane-anchored HIV-1 pan-neutralizing epitope.

Johana Torralba, Igor de la Arada, Angélica Partida-Hanon, Edurne Rujas, Madalen Arribas, Sara Insausti, Claire Valotteau, Javier Valle, David Andreu, José M M Caaveiro and 4 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Structural basis of membrane engagement and polyreactivity control in HIV-1 MPER broadly neutralizing antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Johana TorralbaInstituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.
Igor de la AradaInstituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.ORCID 0000-0001-6777-1238
Angélica Partida-HanonInstitute of Physical Chemistry "Rocasolano" (IQFR-CSIC), Serrano 119, E-28006, Madrid, Spain.
Edurne RujasInstituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.
Madalen ArribasInstituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.ORCID 0000-0001-8421-4708
Sara InsaustiInstituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.
Claire ValotteauLaboratoire Adhesion et Inflammation, INSERM U1067, CNRS UMR 7333, Aix-Marseille Université, Turing Centre for Living systems, Marseille, France.
Javier ValleLaboratory of Proteomics and Protein Chemistry, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003, Barcelona, Spain.
David AndreuLaboratory of Proteomics and Protein Chemistry, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003, Barcelona, Spain.
José M M CaaveiroLaboratory of Global Healthcare, School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 819-0395, Japan.ORCID 0000-0001-5568-2369
María Angeles JiménezInstitute of Physical Chemistry "Rocasolano" (IQFR-CSIC), Serrano 119, E-28006, Madrid, Spain.ORCID 0000-0001-6835-5850
Beatriz ApellánizDepartment of Physiology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad, 7, 01006, Vitoria-Gasteiz, Spain. beatriz.apellaniz@ehu.eus.ORCID 0000-0003-1573-5440
Lorena Redondo-MorataUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017/CIIL-Centre d'Infection et d'Immunité de Lille, F-59000, Lille, France. lorena.redondo-morata@inserm.fr.ORCID 0000-0002-6254-8261
José L NievaInstituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain. joseluis.nieva@ehu.eus.ORCID 0000-0001-6446-5649
University of the Basque Country · ESCentre National de la Recherche Scientifique · FRInstituto de Química Física Blas Cabrera · ESUniversitat Pompeu Fabra · ESIkerbasque · ESKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies against the carboxy-terminal section of the membrane-proximal external region (C-MPER) of the HIV-1 envelope glycoprotein (Env) are considered as nearly pan-neutralizing. Development of vaccines capable of producing analogous broadly neutralizing antibodies requires deep understanding of the mechanism that underlies C-MPER recognition in membranes. Here, we use the archetypic 10E8 antibody and a variety of biophysical techniques including single-molecule approaches to study the molecular recognition of C-MPER in membrane mimetics. In contrast to the assumption that an interfacial MPER helix embodies the entire C-MPER epitope recognized by 10E8, our data indicate that transmembrane domain (TMD) residues contribute to binding affinity and specificity. Moreover, anchoring to membrane the helical C-MPER epitope through the TMD augments antibody binding affinity and relieves the effects exerted by the interfacial MPER helix on the mechanical stability of the lipid bilayer. These observations support that addition of TMD residues may result in more efficient and stable anti-MPER vaccines.

Indexed as

HIV-1EpitopesHIV AntibodiesHIV Envelope Protein gp41Lipid BilayersEpitopesHIV AntibodiesHIV Envelope Protein gp41Lipid Bilayers

Identifiers

PMID36400835
PMCPMC9674588
OpenAlexW4309563896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.